Semiparametric inference on the absolute risk reduction and the restricted mean survival difference
For time-to-event data, when the hazards are non-proportional, in addition to the hazard ratio, the absolute risk reduction and the restricted mean survival difference can be used to describe the time-dependent treatment effect. The absolute risk reduction measures the direct impact of the treatment on event rate or survival, and the restricted mean survival difference provides a way to evaluate the cumulative treatment effect. However, in the literature, available methods are limited for flexibly estimating these measures and making inference on them. In this article, point estimates, pointwise confidence intervals and simultaneous confidence bands of the absolute risk reduction and the restricted mean survival difference are established under a semiparametric model that can be used in a sufficiently wide range of applications. These methods are motivated by and illustrated for data from the Women’s Health Initiative estrogen plus progestin clinical trial.
KeywordsAbsolute risk reduction Clinical trial Non-proportional hazards Restricted mean survival Semiparametric analysis Simultaneous inference
The author would like to thank the reviewers and the Guest Editor for helpful comments and suggestions, which led to an improved version of the manuscript.
- Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M, for the Women’S Health Initiative Investigators, (2003) Estrogen plus progestin and the risk of coronary heart disease. New Eng J Med 349:523–534Google Scholar
- Pollard D (1990) Empirical processes: theory and applications. Institute of Mathematical Statistics, Hayward, CAGoogle Scholar
- Prentice RL, Langer R, Stefanick ML, Howard BV, Pettinger M, Anderson G, Barad D, Curb JD, Kotchen J, Kuller L, Limacher M, Wactawski-Wende J, for the Women’S Health Initiative Investigators (2005) Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the women’s health initiative clinical trial. Am J Epidemiol 162:404–414Google Scholar
- Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. J Am Med Assoc 288:321–333Google Scholar